MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End [Yahoo! Finance]
MIRA Pharmaceuticals, Inc. (MIRA)
Company Research
Source: Yahoo! Finance
company, is pleased to provide a comprehensive update on its recent achievements and scientific advancements as it nears a crucial milestone: the submission of its Investigational New Drug (IND) application by the end of the year. This update highlights the company's strategic progress, significant scientific breakthroughs, and the expertise driving its innovative drug candidates toward clinical trials. Recent Company Highlights Leadership Enhancement with Dr. Itzchak Angel MIRA has strengthened its leadership by appointing Dr. Itzchak Angel as Chief Scientific Advisor. With over 40 years of experience, including a distinguished career at Synthelabo (now Sanofi-Aventis), Dr. Angel was instrumental in the development and regulatory approval of several key drugs, such as Ambien, Xatral and Mizolen. His expertise in advancing drug candidates from early research through clinical trials is now guiding MIRA's pipeline?. Scientific Progress with Ketamir-2 MIRA has made significant
Show less
Read more
Impact Snapshot
Event Time:
MIRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRA alerts
High impacting MIRA Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MIRA
News
- MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA [Yahoo! Finance]Yahoo! Finance
- MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDAAccesswire
- MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough StudyAccesswire
- MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-EndAccesswire
- MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP ReceptorAccesswire
MIRA
Sec Filings
- 9/12/24 - Form 8-K
- 9/10/24 - Form 8-K
- 9/6/24 - Form 144/A
- MIRA's page on the SEC website